Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease (TAMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02811653
Recruitment Status : Unknown
Verified June 2016 by Centre Hospitalier Universitaire, Amiens.
Recruitment status was:  Recruiting
First Posted : June 23, 2016
Last Update Posted : June 23, 2016
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire, Amiens

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
In AD (Alzheimer disease), the anatomic correlates of attention disorders (as evaluated by motor slowing) have not been thoroughly characterized.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Device: Brain MRI Other: neuropsychological evaluation Biological: Blood Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 155 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease
Study Start Date : December 2015
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Alzheimer disease
Alzheimer disease patients Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation
 Device: Brain MRI
Other: neuropsychological evaluation
Biological: Blood
Active Comparator: control

Healthy age- and gender-matched volunteers will be recruited into the study from the general population.

Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation

 Device: Brain MRI
Other: neuropsychological evaluation
Biological: Blood


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. median SRT (simple reaction time) to a stimulus (in milliseconds) [ Time Frame: Day 0 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients

    • Age between 40 and 85
    • French mother tongue
    • Consulting at the Amiens Memory Resource and Research Centre (CMRR) for:
    • MCI, according to Albert et al.'s criteria (Albert et al., 2011)
    • Mild dementia (MMSE>20) due to AD, according to McKhann's criteria (McKhann et al., 2011).
    • Mild dementia due to LBD, according to McKeith et al.'s criteria (McKeith et al., 2005).
    • Mild dementia due to FTLD, according to Rascovsky et al.'s criteria (Rascovsky et al., 2011).
    • Social security coverage

  • Healthy controls

    • Healthy age and gender matched volunteers will be recruited into the study from the general population.

Exclusion Criteria:

  • Reading or writing difficulties related to a learning disorder or illiteracy.

  • A medical history with a potentially significant impact on cognition (non-corrected thyroid disorders or heart failure):

    • NYHA stage IV dyspnoea.
    • respiratory impairment requiring oxygen therapy.
    • liver impairment.
    • kidney failure, progressing neoplastic disease, or past or present alcohol abuse.

  • Past or present neurological disorders other than those having prompted consultation in the Memory Clinic:

    • stroke.
    • meningitis or encephalitis.
    • severe head injury.
    • sensorimotor impairments (sensory, proprioceptive, cerebellar and visual impairments).
    • epilepsy (requiring ongoing treatment),
    • psychiatric disorders (other than treated depression).
    • treatment with psychotropic medications (other than anxiolytics or antidepressant withdrawn or initiated in the previous month). Patients with parkinsonian syndrome were examined in the "on-drug" state.
  • Impossibility to perform a neuropsychological evaluation or brain MRI.
  • Withdrawal from the study at any time, if desired.
  • Pregnancy

  • Contra-indication to MRI:

    • nerve stimulators
    • cochlear implants
    • ferromagnetic foreign bodies close to nervous structures in the eye or brain
    • cerebral shunts
    • dental appliances
  • Legal guardianship or incarceration.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02811653


Contacts
Layout table for location contacts
Contact: Daniela ANDRIUTA, PhD +33 3 22 66 82 40 andriuta.daniela@chu-amiens.fr

Locations
Layout table for location information
France
CHU Amiens Recruiting
Amiens, France, 80054
Contact: Daniela ANDRIUTA, PhD    +33 3 22 66 82 40    andriuta.daniela@chu-amiens.fr   
Sponsors and Collaborators
Centre Hospitalier Universitaire, Amiens
Investigators
Layout table for investigator information
Principal Investigator: Daniela ANDRIUTA, PhD CHU Amiens
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire, Amiens
ClinicalTrials.gov Identifier: NCT02811653    
Other Study ID Numbers: PI2015_843_0003
First Posted: June 23, 2016    Key Record Dates
Last Update Posted: June 23, 2016
Last Verified: June 2016
Keywords provided by Centre Hospitalier Universitaire, Amiens:
Motor slowing
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
 Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders